December 28, 2014 5:27 PM ET

Pharmaceuticals

Company Overview of Amersham Biosciences Corporation

Company Overview

As of 2004, Amersham Biosciences Corporation was acquired by General Electric Company. Amersham Biosciences Corporation manufactures and supplies biopharmaceutical products. It also offers biotechnology systems, products, and services used in gene and protein research, drug discovery, and development. The company was formerly known as Amersham Pharmacia Biotech, Inc. The company is based in Piscataway, New Jersey.

800 Centennial Avenue

P.O. Box 1327

Piscataway, NJ 08855-1327

United States

4,150 Employees

Phone:

732-457-8000

Fax:

732-457-0557

Key Executives for Amersham Biosciences Corporation

Amersham Biosciences Corporation does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Pernix Therapeutics, LLC United States
ZP Opco, Inc. United States
Gelesis, Inc. United States
Bexion Pharmaceuticals, LLC United States
Arogen, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Amersham Biosciences Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.